review glp-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 receptor agonists show promise

GLP-1 pentareceptor agonist From September 15 to 19, 2025, the 61st annual meeting of the European Association for diabetes Research (EASD) was held in Vienna

Every woman in the room is over 40

Strength training does not have to be extreme, but it should be consistent and appropriate for the patients age, fitness level, joint health, and medical history

Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis

Patients across Westchester County who enroll can expect regular check-ins, attention to how they are tolerating the medication, and honest conversations about progress, side effects, and lifestyle